Peptide Initiative

Peptides · Peptide comparison

Gonadorelin (GnRH) vs Prostamax

The master hormone that controls your reproductive system and fertility

Prostate-specific tetrapeptide bioregulator (Lys-Glu-Asp-Pro) that normalizes prostatic epithelial differentiation through chromatin remodeling at prostate gene promoters, restores the proliferation-apoptosis balance disrupted in benign prostatic hyperplasia, and reduces inflammatory cytokine signaling in aging prostate tissue

  • Hormone Support
  • Hormone Support

At a glance

Quick comparison

Dose rangeGonadorelin (GnRH)100–100 mcgProstamax0.01–100 mcg/kg
FrequencyGonadorelin (GnRH)Once dailyProstamaxOnce daily
AdministrationGonadorelin (GnRH)Subcutaneous injectionProstamaxSublingual (enteric-coated capsules)
Cycle lengthGonadorelin (GnRH)Ongoing/indefiniteProstamax12+ weeks
Onset speedGonadorelin (GnRH)Moderate (1-2 weeks)ProstamaxGradual (3-4 weeks)
Evidence levelGonadorelin (GnRH)Moderate human trials (Phase 1-2)ProstamaxLimited human trials

Efficacy

Benefit ratings

Reproductive Health

Gonadorelin (GnRH)95%
ProstamaxNo recorded rating

Hormone Balance

Gonadorelin (GnRH)90%
ProstamaxNo recorded rating

Ovulation Support

Gonadorelin (GnRH)88%
ProstamaxNo recorded rating

Prostate Health

Gonadorelin (GnRH)No recorded rating
Prostamax94%

Urinary Function

Gonadorelin (GnRH)No recorded rating
Prostamax88%

Tissue Inflammation

Gonadorelin (GnRH)No recorded rating
Prostamax82%

Technical data

Compound specifications

Gonadorelin (GnRH)

Molecular formula
C55H75N17O13
Molecular weight
1182.3
Half-life
2-4 minutes
Bioavailability
Varies by route: ~5-20% (intranasal), 100% (IV/IM injections)
CAS number
34973-08-5

Prostamax

Molecular formula
C20H33N5O9
Molecular weight
487.5 g/mol
Half-life
Short plasma half-life typical of tetrapeptides (minutes to hours); biological effects persist for weeks to months through chromatin remodeling at prostate gene promoters; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1) in oral formulation; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to short tetrapeptide structure with proline conferring conformational stability
CAS number
Not publicly registered

Protocols

Dosing compared

Gonadorelin (GnRH)

Subcutaneous

  • 100 mcgSingle dose · One-time diagnostic testFDA-labeled gonadotropin (LH/FSH) stimulation test for pituitary reserve; 100 mcg given once subcutaneously (or IV), with LH measured at 0, 15, 30, 45, 60 and 120 minutes (Factrel) [4].

Intravenous

  • 5 mcg per pulse (range 1-20 mcg)Every 90 minutes via pulsatile pump · One or more ovulatory cycles; reassessed at 21-day intervalsFDA-labeled pulsatile regimen for ovulation induction in hypothalamic amenorrhea (Lutrepulse); intravenous pulsatile delivery gave better results than subcutaneous [5]. The 2-4 minute half-life makes pulsatile delivery essential.

Prostamax

Intramuscular

  • 0.01-100 mcg/kgOnce daily · 10-40 daysDose from a single-institute patent report in 35 chronic-prostatitis patients [6]. The wide range reflects dose-finding within that single report.

Oral

  • ~10 mgOnce daily · 10-30 day courseCapsule form reflecting bioregulator product labeling and practice [1].

Applications

Best suited for

Gonadorelin (GnRH)

Improving fertility and conception chances
Gonadorelin (GnRH) is particularly well-suited for individuals focused on improving fertility and conception chances. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Regulating irregular menstrual cycles
Gonadorelin (GnRH) is particularly well-suited for individuals focused on regulating irregular menstrual cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhancing reproductive hormone levels
Gonadorelin (GnRH) is particularly well-suited for individuals focused on enhancing reproductive hormone levels. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting natural pregnancy attempts
Gonadorelin (GnRH) is particularly well-suited for individuals focused on supporting natural pregnancy attempts. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Prostamax

Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization
Prostamax is particularly well-suited for individuals focused on age-related benign prostatic hyperplasia (bph) requiring tissue-level normalization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Prostate geroprotection — preserving prostatic epithelial function during aging
Prostamax is particularly well-suited for individuals focused on prostate geroprotection — preserving prostatic epithelial function during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic prostatitis support through anti-inflammatory tissue-level mechanisms
Prostamax is particularly well-suited for individuals focused on chronic prostatitis support through anti-inflammatory tissue-level mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting male genitourinary health
Prostamax is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting male genitourinary health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Gonadorelin (GnRH)

Common

  • Mild headache
  • Local injection site reactions (redness, swelling)
  • Temporary hot flashes
  • Mood changes or emotional sensitivity
  • Nausea or mild stomach upset
  • Allergic skin reactions
  • Dizziness or lightheadedness
  • Temporary changes in vision
  • Joint or muscle aches
  • Insomnia or sleep disturbances
  • Severe allergic reactions (difficulty breathing, swelling)
  • Severe hormonal imbalance symptoms
  • Ovarian hyperstimulation syndrome (OHSS)
  • Signs of blood clots (chest pain, leg swelling)
  • Severe mood changes or depression

Serious

  • Severe allergic reaction

Prostamax

Common

  • Injection site reaction
  • Mild fatigue
  • Urinary frequency changes
  • Mild headache

Uncommon

  • Mild pelvic discomfort

Serious

  • No documented serious adverse effects

Research status

Safety & evidence

Gonadorelin (GnRH)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Previously FDA approved: FACTREL (1982) as a diagnostic test of pituitary gonadotropin reserve and LUTREPULSE (1989) for ovulation induction. Both human products are discontinued in the US.
Safety overview
Gonadorelin is native GnRH and carries the safety profile established over 40+ years of clinical use in reproductive endocrinology. As the body's natural hormone, it produces minimal local side effects when dosed appropriately. The critical safety concern with gonadorelin is the initial flare effect within 24-48 hours of first dose—temporary elevation in FSH and LH—which can paradoxically suppress sex hormones before the desired stimulation occurs. This flare makes gonadorelin unsuitable for some conditions and explains why synthetic analogs (agonists, antagonists) are preferred in many modern fertility protocols.

Contraindications

  • Pregnancy or breastfeeding
  • Hormone-sensitive cancers (breast, prostate, ovarian)
  • Severe pituitary or hypothalamic disease
  • Undiagnosed abnormal vaginal bleeding
  • Known hypersensitivity to GnRH

Prostamax

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Prostamax (proprietary peptide blend) demonstrates limited published safety data; primarily used in clinical practice based on observational evidence. No serious adverse events reported in clinical use; mild gastrointestinal tolerance issues occasionally reported. Derived from bovine prostatic tissue; potential allergenicity in beef-sensitive individuals requires screening. Quality control and standardization vary across manufacturers.

Contraindications

  • Known or suspected prostate cancer — potential modulation of prostatic gene expression requires oncological clearance
  • Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, proline)
  • Severe urinary retention requiring surgical intervention — epigenetic therapy cannot address acute obstruction
  • Concurrent anti-androgen therapy without medical supervision — potential interaction with hormonal mechanisms

Decision guide

Which is right for you?

Gonadorelin (GnRH)

Choose Gonadorelin (GnRH) if…

  • Improving fertility and conception chances
  • Regulating irregular menstrual cycles
  • Enhancing reproductive hormone levels
  • Supporting natural pregnancy attempts

Prostamax

Choose Prostamax if…

  • Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization
  • Prostate geroprotection — preserving prostatic epithelial function during aging
  • Chronic prostatitis support through anti-inflammatory tissue-level mechanisms
  • Comprehensive Khavinson bioregulator protocols targeting male genitourinary health